REJUVENATION TECHNOLOGIES, INC.
Biotech · Private
Lipid nanoparticle-delivered telomerase mRNA therapy to extend telomeres and restore hepatocyte regenerative capacity in alcoholic hepatitis
- Grants
- $3.9M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 0 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA | $272,403 | |
| Federal grant | Department of Health and Human Services · Phase II · TERT mRNA lipid nanoparticles to extend telomeres to treat pulmonary fibrosis | $299,987 | |
| Federal grant | Department of Health and Human Services · Phase II · TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis | $626,743 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis | $1,858,106 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic | $520,303 | |
| Federal grant | Department of Health and Human Services · Phase I · Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells | $324,998 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1380 | Monopar Therapeutics | — | $2.1M |
| 1381 | INFLAMED, INC. | — | — |
| 1382 | XPOSE THERAPEUTICS, INC. | — | — |
| 1383 | REJUVENATION TECHNOLOGIES, INC. | — | — |
| 1384 | CHESAPEAKE GENOMIC SYSTEMS, LLC | — | — |
| 1385 | STRESS THERAPEUTICS, INC. | — | — |
| 1386 | Atrapos Therapeutics, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Delivery Of Rna Encoding Tert Using Lipidsapplication
- Compositions And Methods For Delivery Of Rnaapplication
- Compositions And Methods For Broad Delivery Of Rna To Tissueapplication
- Compositions And Methods For Broad Delivery Of Rna To Tissueapplication
- Compositions And Methods For Delivery Of Rnaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.